icone plus
Contact
Abonnez-vous aux actualités
Reason for request
Inclusion
Clinical Benefit
Substantial
the actual benefit of HEMANGIOL 3.75 mg/ml oral solution is substantial in the indication in the Marketing Authorisation.
Clinical Added Value
moderate
HEMANGIOL 3.75 mg/ml oral solution provides a moderate improvement in actual benefit (IAB III) in the treatment of proliferating infantile haemangioma requiring systemic therapy.
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
N84vuK43zHemA7XK